



Working out what works....



Martin Landray @MartinLandray · 8 Oct 2020

The **RECOVERY trial** has now answered 3 questions for hospitalised COVID pts:

- HCQ is not effective
- Lopinavir is not effective
- **Dexamethasone** reduces mortality for patients on oxygen or mechanical ventilators

All 3 results have changed medical practice & benefited patients



OxPrimaryCareSci
@OxPrimaryCare

BREAKING NEWS: PRINCIPLE trial reports the corticosteroid budesonide is the first widely available, inexpensive drug found to shorten recovery time in non-hospitalised patients with COVID-19. It is now available in UK [#primarycare](#) on a case-by-case basis. principletrial.org/news/asthma-dr...

GenOMICC Study @GenomiccStudy · Dec 11, 2020

The GenOMICC study has now found 5 DNA changes that make people susceptible to life-threatening COVID-19. These changes are linked to 5 genes and in some cases lead us directly to therapeutic targets. (3/8)



University of Oxford
@UniofOxford

VACCINE UPDATE: New study shows that the [#OxfordVaccine](#) offers protection of 76% up to 12 weeks after a single dose, with further data supporting a 4-12 week dosing interval:



Peter Horby @PeterHorby · Nov 19, 2020

🔥 news on tocilizumab treatment in critically ill COVID-19 patients- REMAP-CAP declaring benefit twitter.com/remap_cap/stat...

....and what doesn't



Ymchwil Iechyd
a Gofal Cymru
Health and Care
Research Wales



Peter Horby @PeterHorby · Dec 14, 2020

New RECOVERY result. In patients hospitalised with COVID-19, azithromycin did not provide any clinical benefit. 28 day mortality (19% vs 19%) (rate ratio 1.00; 95% confidence interval [CI] 0.90-1.12; p=0.99). No effect on secondary outcomes either.

medrxiv.org/content/10.110...



Martin Landray
@MartinLandray

On the advice of the DMC, recruitment to the convalescent plasma arm of the RECOVERY trial has now closed:

Preliminary analysis: No convincing evidence of worthwhile mortality benefit either overall or in any pre-specified subgroup.



remap-cap @remap_cap · Dec 23, 2020

On the recommendation of the Data Safety and Monitoring Board, [#REMAPCAP](#) has paused randomization to therapeutic [#anticoagulation](#) among critically ill patients with [#COVID19](#) for futility.

6


236

298



COVID19 research delivery

94 COVID19 studies set up and open




32 COVID19 UPH Studies
36,500 Welsh Participants



112 patients



8 sites
1251 patients



6 sites
282 patients




3 Vaccine Trials
(2 in set up)



days to open to recruitment
(UPH studies only)



days (median) from opening
to recruitment of 1st patient
(UPH studies only)



Programme: Looking to the future together

Wednesday 21 April

13:15	Research and Innovation in health and care: learning from the pandemic	Professor Kieran Walshe, Director HCRW
13:35	UK Vision for Clinical Research	Carys Thomas, Welsh Government
14:15	Participant in Research Experience Survey	Dr Andi Skilton, NIHR
14:35	Contracting and funding in a national model	Dr Helen Hodgson, Fiona Dunn HCRW
15:15	Digital Health and Care Wales and the future of research within Wales	Rachael Powell, NWIS
15:35	The One Wales approach to COVID-19 vaccine research	Dr Andrew Freedman, Dr Orod Osanlou, Principal Investigators

Thursday 22 April

09:15	Positioning Wales as a key player in the COVID-19 research effort	Felicity Waters, HCRW
09:45	Supporting the care home community through research during pandemics and beyond	Stephanie Green, ENRICH Cymru
10:15	Five top tips for communication impact	Ginger Training
11:05	HRA and Health and Care Research Wales: leading, learning and recovering from COVID	Professor Matt Westmore, HRA